You watched Sarah's story.
Same 14-specialist analysis. Your case.
The research your oncologist doesn't have time to compile, delivered in 48 hours.
Start My Brief — $99
- 30-50 page personalized briefing
- 48-hour delivery
- Refund + free re-brief if not useful
People are paying for the research no one else will compile.
"What keeps me up at night since my daughter was born is wondering when this will come back."
— Nicholas, Hodgkin's survivor
"I finished my last round of ABVD chemo two years ago and I'm in remission — which is amazing. But nobody really wants to talk about what to watch for now. I wanted someone to put together what the research says about survivorship — not just 'you're cured, go live your life.'"
— Sarah, 34, Hodgkin's survivor
This is for Nicholas. And Sarah. And anyone whose oncologist said you're cured when it didn't actually feel cured.
What you'll get back
Real findings from Sarah's brief. Each rated Strong / Moderate / Emerging by how many specialists converged.
Strong
Cardiac Monitoring Post-Doxorubicin
Doxorubicin (part of ABVD) is a known cardiotoxin. Research shows cumulative dose-dependent cardiac damage that can manifest years after treatment. Regular echocardiography and emerging biomarker panels can detect early dysfunction.
Monitoring protocols are non-invasive and well-established in survivorship guidelines.
Strong
Thyroid Function Surveillance
Radiation to the mediastinum and neck damages thyroid tissue. Hypothyroidism develops in a significant percentage of survivors, often years later, and can mimic cancer fatigue if undetected.
Simple blood test. Thyroid replacement therapy, if needed, is safe and well-tolerated long-term.
Sarah's full brief was 47 pages. Yours will be tailored to your specific question.
How it works
- Tell us your case — One paragraph, in your own words. 60 seconds.
- 14 specialists analyze — Independently, in parallel. Each pulls from PubMed, ClinicalTrials.gov, FDA labels.
- Convergence ranked — Every finding rated Strong / Moderate / Emerging by how many specialists confirmed it. Disagreement is data.
- Briefing delivered — 30-50 pages in your inbox in 48 hours. With references. With questions for your doctor.
14 specialist agents. Modeled after pioneers.
Each agent represents a domain of medicine, named for the scientist who defined it.
- Yamanaka — Stem Cells & Regenerative
- Doudna — Gene Therapy & CRISPR
- Pauling — Nutraceuticals
- Ornish — Lifestyle Medicine
- Ashburn — Drug Repurposing
- Campbell — Antiparasitics & Off-Label
- Sonnenburg — Microbiome
- Sacks — Pathophysiology
- Merrifield — Peptides
- Karplus — Computational
- Thomas — Cell-Based Therapies
- Blackburn — Hormonal & Women's Health
- Bhatt — Diagnostics
- Allison — Immunotherapy
Each agent independently reviews your case. We deliver only what multiple specialists converge on.
Why $99
At a top academic center — Mayo Clinic, MD Anderson, Cleveland Clinic — your case might be reviewed by 5-7 sub-specialists in a tumor board. That access takes weeks of referrals, often travel, and runs $2,000–$5,000 just for the consult.
Insight Swarm convenes 14 specialist agents for your case. Same shape of analysis. 48 hours instead of 6 weeks. $99 instead of $5,000+.
| Where | Cost | Time |
| Mayo / MD Anderson tumor board | $2,000–5,000 | 4–8 weeks |
| Patient advocacy services | $300–2,000 | days of intake |
| ChatGPT or Perplexity | free, won't search PubMed correctly | minutes |
| Insight Swarm | $99 | 48 hours |
The promise
Read your briefing. If we didn't surface anything you couldn't easily Google, reply to the delivery email within 7 days. Full refund. AND we'll run a second brief on a different question, free. No questions, no upsells.
Reviewed by Medical Advisor at Medical Meditation Corporation.
Not medical advice — research summary intended to inform conversations with your medical team.